Document Detail

Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
MedLine Citation:
PMID:  17601426     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. DESIGN: Retrospective case series. METHODS: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. RESULTS: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. CONCLUSIONS: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.
Anat Galor; Sandra J Ference; Arun D Singh; Michael S Lee; Glen H J Stevens; Victor L Perez; David M Peereboom
Related Documents :
11475366 - Multifocal erg and full-field erg in patients on long-term vigabatrin medication.
22234076 - Terlipressin facilitates gastric and autonomic system dysfunctions in liver cirrhosis.
17141316 - Natural history of the visual impairment of relapsing neuromyelitis optica.
12954316 - Systematic underablation in laser in situ keratomileusis: ablation pattern identified b...
11120436 - The prevalence and stability of an executive processing deficit, response inhibition, i...
17906986 - Essential thrombocytemia and acute coronary syndrome: clinical profile and association ...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of ophthalmology     Volume:  144     ISSN:  0002-9394     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-02     Completed Date:  2007-07-17     Revised Date:  2008-01-29    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  45-49     Citation Subset:  AIM; IM    
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / administration & dosage,  adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Blood-Brain Barrier / drug effects*
Brain Neoplasms / drug therapy*
Carotid Artery, Internal
Catheterization, Peripheral
Cyclophosphamide / administration & dosage
Cytarabine / administration & dosage
Etoposide / administration & dosage
Fluorescein Angiography
Injections, Spinal
Lymphoma / drug therapy*
Mannitol / administration & dosage,  adverse effects*
Methotrexate / administration & dosage,  adverse effects*
Middle Aged
Pigment Epithelium of Eye / drug effects,  pathology
Retinal Diseases / chemically induced*,  diagnosis
Retrospective Studies
Tomography, Optical Coherence
Vertebral Artery
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 147-94-4/Cytarabine; 33419-42-0/Etoposide; 50-18-0/Cyclophosphamide; 59-05-2/Methotrexate; 69-65-8/Mannitol
Comment In:
Am J Ophthalmol. 2007 Dec;144(6):976; author reply 976   [PMID:  18036877 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Jean Darier and his précis.
Next Document:  Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis.